

Product Specification Sheet

Meningitis B neisserial Neisseria adhesin A (Men B NADA) Positive and negative Controls

□ MBNA21-HPC	Meningitis B neisserial Neisseria adhesin A (Men B NADA) positive control serum	Size:2 ml
□ MBNA21-HNC	Meningitis B neisserial Neisseria adhesin A (Men B NADA) negative control serum	Size:2 ml

Meningococcal meningitis, a form of meningococcal disease, is a serious bacterial infection. It causes meningitis, meningococemia, septicemia, and rarely carditis, septic arthritis, or pneumonia. Unlike viral meningitis, it can potentially kill an otherwise healthy young person within a few days after the first symptoms appear. Meningitis is inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. It is life-threatening because of the inflammation's proximity to the brain and spinal cord; therefore the condition is classified as a medical emergency. *Neisseria meningitidis* has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. Six serogroups, **A, B, C, Y, W135 and X** are responsible for virtually all cases of the disease in humans.

The capsular polysaccharide of Men B is a self antigen that cannot be used to make a vaccine. The antigens selected by reverse vaccinology were prioritized based on their ability to induce broad protection. The proteins that met these criteria were called **Genome-derived Neisseria Antigens**. The most abundant antigen is **PorA**, which is variable and induces only strain-specific protection. Less abundant but more conserved antigens are **FHBP (factor H-binding protein) NadA (Neisseria adhesin A) and NHBA (Neisseria heparin-binding antigen)**.

FHBP (or **GNA1870**, 282 a.a.) is a surface exposed lipoprotein that binds human factor H, enhancing the ability of the bacterium to resist complement-mediated killing. It is classified into 3 genetic and immunogenic variants: **NADA-1, NADA-2 and NADA-3**, which are not cross-protective, and can be further divided into sub variants **NADA-1.x, NADA-2.x and NADA-3.x**. **NadA** (or **GNA1994**, 362 a.a) is an adhesin that was included in the MenB vaccine as single trimeric soluble protein, devoid of the membrane anchor domain. **NadA** is well conserved, and five variants have been identified. **NadA-1, NadA-2, and NadA-3** show highly conserved sequences. **NadA-4 and NadA-5** are less common, and associated with carrier strains. **NHBA** (or **GNA2132**, 427 a.a) is a surface-exposed lipoprotein which binds heparin in vitro through an arginine-rich region. The NHBA domain fold consists of an 8-strand β -barrel that closely resembles the C-terminal domains of *N. meningitidis* factor H-binding protein and transferrin-binding protein B. This common fold together with more subtle structural similarities suggest a common ancestor for these important antigens and a role of the β -barrel fold in inducing immunogenicity against *N. meningitidis*.

A multi component vaccine against serogroup B meningitis **Bexsero® (4CMenB)**, has just completed phase III clinical trials in infants. There are currently 3 vaccines available in the US, all quadrivalent in nature, targeting serogroups A, C, W-135 and Y. Two conjugate vaccines (**MCV-4**), **Menactra** (Polysaccharides conjugated to Diphtheria Toxoid) and **Menveo** (Conjugated to toxoid diphtheria mutant CRM197); One polysaccharide vaccine (**MPSV-4**), **Menomune**, produced by Sanofi Pasteur; **Mencevax** (GlaxoSmithKline, CRM197 conjugate) and **NmVac4-A/C/Y/W-135** (JN-International Medical Corporation, conjugated to Diphtheria Toxoid) are used worldwide, but have not been licensed in the United States.

Source and Forms of Controls

Human Men B NADA protein antibody controls were prepared from human sera that were infected with the Men B virus or had antibodies due to natural infection. The controls are tested in ELISA using purified MenB NADA protein coated plates.

Cat# MBNA21-HNC; MenB NADA antibody –ve control

Human serum in a stabilizing buffer supplied as liquid (2 ml) or in lyophilized form. Reconstitute powder with 2 ml distilled water. When tested undiluted the –ve control yielded Men B NADA antibody ELISA # **600-900-HNG**, A450=<0.400. For testing in other ELISAs or applications, users must determine the sample dilutions.

Cat# MBNA21-HPC; MenB NADA antibody +ve control

Human serum in a stabilizing buffer supplied as liquid (2 ml) or in lyophilized form. Reconstitute powder with 2 ml distilled water. When tested undiluted the +v control yielded. Men B NADA antibody ELISA # **600-900-HNG** A450=>1.500. For testing in other ELISAs or applications, users must determine the sample dilutions.

Store –ve or +ve controls at 4°C for 1-3 months or store frozen at -20°C in suitable size aliquots.

Stability: 6-12 months at –20°C or below.

Shipping: 4°C for solutions and room temp for powder.

References: Veronica E (2011) J Biol Chem 286: 41767-41775; David M. Vu (2011) Vaccine 29: 1968–1973. Miguel O (2014) Drugs ;74: 15–30.; Seil KL (2009) Infect Immun. 77(1): 292–299. Masignani (2003) JEM 197 (6): 789

*This product is for In vitro research use only.

Related material available from ADI

FHBP11-C	Purified Meningitis B factor H binding protein (MenB fHbp) control for western blot
FHBP11-NC	Human Meningitis B factor H binding protein (MenB fHbp) antibody negative control serum
FHBP11-PC	Human Meningitis B factor H binding protein (MenB fHbp) antibody positive control serum
FHBP11-S	Rabbit Anti-Meningitis B factor H binding protein (MenB fHbp) antiserum
FHBP15-R-10	Recombinant (E.coli, his tag) Purified Meningitis B factor H binding protein (MenB fHbp) (>95%)
NADA11-S	Anti-Meningitis B neisserial adhesin A (MenB Nad A) antiserum
NADA15-R-10	Recombinant (E.coli, his tag) Purified Meningitis B neisserial adhesin A (MenB NadA) protein (>95%)
NHBA11-C	Purified Meningitis B neisserial heparin-binding antigen (MenB NHBA) control for western blot
NHBA11-NC	Human Meningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum
NHBA11-PC	Human Meningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum
NHBA11-S	Rabbit Anti-Meningitis B neisserial heparin-binding (MenB NHBA) antigen antiserum
NHBA15-R-10	Recombinant (E.coli, his tag) Purified Meningitis B neisserial heparin-binding antigen (MenB NHBA) (>95%)

MBNA21-HPC-MenB-NadA 151124SV